Biotechnology

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

--Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses --Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent applicati...

2023-01-26 21:08 2932

ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies

NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative medicine industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or "...

2023-01-26 12:11 1887

iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax

* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...

2023-01-26 10:34 1756

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated byHarbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hype...

2023-01-26 09:22 2336

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

SEOUL, South Korea, Jan. 26, 2023 /PRNewswire/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo  gene editing therapies. This c...

2023-01-26 09:00 2853

ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies

NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or ...

2023-01-26 08:11 2057

PlumCare RWE partners with Lifebit on Greece's newborn genomic sequencing program, BeginNGS

* PlumCare RWE and Lifebit enter a three-year partnership to support Greece's pioneering national newborn genomic sequencing program, BeginNGS. * Researchers will be able to access and analyse data securely in combination with global cohorts, whilst ensuring data is kept safe, private and in p...

2023-01-25 23:00 2714

Singleron launches single cell eQTL analysis as part of their sequencing service

A new bioinformatic pipeline to investigate single cell eQTL analysis is now offered in the sequencing service from Singleron Biotechnologies. COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at Singleron Biotechnologies , a leader in single cell sequ...

2023-01-25 19:00 1832

IVI opens Country Office in Austria

SEOUL, South Korea, Jan. 25, 2023 /PRNewswire/ -- The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, announced today the launch of an IVI Count...

2023-01-25 11:17 2357

DiscGenics Announces Positive Two-Year Clinical Data from U.S. Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease

Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar DDD. SALT LAKE CITY, Jan. 25, 2023 /PRNewswire/ -- DiscGenics, I...

2023-01-25 08:35 2189

Complete Genomics to Announce New Product Launches at AGBT General Meeting

SAN JOSE, Calif., Jan. 24, 2023 /PRNewswire/ -- Complete Genomics Inc. , a global life science tools leader and subsidiary of MGI Tech Co., Ltd. ("MGI"), today announced it plans to launch three new products at the Advances in Genome Biology and Techn...

2023-01-24 20:30 2099

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...

2023-01-20 21:50 4301

SK bioscience Appoints New Executives to Accelerate New Growth Strategies

* Two biopharmaceutical experts join SK bioscience to strengthen the future strategies * With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth SEOUL, South Korea, Jan. 20, 2023 /PRNewswire/ -- SK ...

2023-01-20 20:00 2571

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...

2023-01-20 18:00 3132

BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS

TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at theAmerican Association for Cancer Research (AACR) <...

2023-01-20 13:10 2062

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in t...

2023-01-20 09:50 2153

NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS

* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being considered by PHARMAC for reimbursement * Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 19, 2023 /PR...

2023-01-20 02:00 2322

Seragon Announces RESTORIN®, the Most Advanced Anti-Aging Nutraceutical to Date

IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging. RESTORIN integrates a series of patented technologies fromHarvard University, Mayo Clinic, and Scripps Research to boost cellular nicotinam...

2023-01-19 23:10 3732

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global De...

2023-01-19 23:05 3895

Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH

SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today reported positive top-line results from the Phase 2a RISE clinical trial of HPG1860, a next gene...

2023-01-19 23:00 2239
1 ... 88899091929394 ... 280